CA3172649A1 - Masked il-2 cytokines and their cleavage products - Google Patents
Masked il-2 cytokines and their cleavage productsInfo
- Publication number
- CA3172649A1 CA3172649A1 CA3172649A CA3172649A CA3172649A1 CA 3172649 A1 CA3172649 A1 CA 3172649A1 CA 3172649 A CA3172649 A CA 3172649A CA 3172649 A CA3172649 A CA 3172649A CA 3172649 A1 CA3172649 A1 CA 3172649A1
- Authority
- CA
- Canada
- Prior art keywords
- cytokine
- masked
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003824P | 2020-04-01 | 2020-04-01 | |
| US63/003,824 | 2020-04-01 | ||
| US202063118571P | 2020-11-25 | 2020-11-25 | |
| US63/118,571 | 2020-11-25 | ||
| PCT/US2021/025103 WO2021202675A1 (en) | 2020-04-01 | 2021-03-31 | Masked il-2 cytokines and their cleavage products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3172649A1 true CA3172649A1 (en) | 2021-10-07 |
Family
ID=77928454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3172649A Pending CA3172649A1 (en) | 2020-04-01 | 2021-03-31 | Masked il-2 cytokines and their cleavage products |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230151072A1 (https=) |
| EP (1) | EP4126247A4 (https=) |
| JP (1) | JP7735306B2 (https=) |
| KR (1) | KR20220161404A (https=) |
| CN (1) | CN115942976A (https=) |
| AU (1) | AU2021245922A1 (https=) |
| BR (1) | BR112022019689A2 (https=) |
| CA (1) | CA3172649A1 (https=) |
| IL (1) | IL296915A (https=) |
| MX (1) | MX2022012311A (https=) |
| PH (1) | PH12022552627A1 (https=) |
| TW (1) | TW202204388A (https=) |
| WO (1) | WO2021202675A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| CA3100005A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| CN120463822A (zh) | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| AU2021254283B2 (en) * | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2022115865A2 (en) * | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| JP2024511387A (ja) | 2021-03-16 | 2024-03-13 | シートムエックス セラピューティクス，インコーポレイテッド | マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
| WO2023161853A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| MX2024010488A (es) * | 2022-02-28 | 2024-09-05 | Xilio Dev Inc | Citocinas dirigidas y metodos de uso de estas. |
| WO2023164286A1 (en) * | 2022-02-28 | 2023-08-31 | Xilio Development, Inc. | Engineered cd122 compositions and methods thereof |
| KR20250039361A (ko) * | 2022-07-15 | 2025-03-20 | 실리오 디벨럽먼트, 인크. | 담체로서의 조작된 절단성 Fc 도메인 및 이의 사용 방법 |
| CN117917438A (zh) * | 2022-10-21 | 2024-04-23 | 北京诺诚健华医药科技有限公司 | 抗体融合蛋白及其制备和应用 |
| WO2024150175A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| US20240417436A1 (en) | 2023-01-11 | 2024-12-19 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| TW202517789A (zh) * | 2023-07-04 | 2025-05-01 | 香港商禮邦醫藥（香港）有限公司 | Ｋｌｋ１融合蛋白質的製備方法 |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025049948A1 (en) * | 2023-08-30 | 2025-03-06 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
| WO2025162454A1 (zh) * | 2024-02-02 | 2025-08-07 | 北京昌平实验室 | 双特异性抗体和细胞因子融合蛋白及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| EP2553101A4 (en) * | 2010-04-02 | 2013-09-04 | Univ Rochester | PROTEASE-ACTIVATED CYTOKINES |
| HUE029139T2 (hu) * | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| EP2882775B1 (en) * | 2012-08-09 | 2018-02-14 | Roche Glycart AG | Asgpr antibodies and uses thereof |
| US9605084B2 (en) * | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| CN108218993B (zh) * | 2018-01-05 | 2020-11-17 | 阿思科力(苏州)生物科技有限公司 | 一种以robo1为靶点的双特异性抗体及其制备和应用 |
| WO2019173832A2 (en) * | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
| AU2019271148B9 (en) * | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| US12459980B2 (en) * | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| CN112867503A (zh) * | 2018-08-24 | 2021-05-28 | 希望之城 | 掩蔽的细胞因子缀合物 |
| CN120463822A (zh) * | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| JP2022533254A (ja) | 2019-05-24 | 2022-07-21 | プロヴィヴァ セラピューティクス （ホン コン） リミテッド | Ｉｌ－２組成物およびその使用方法 |
-
2021
- 2021-03-31 JP JP2022560205A patent/JP7735306B2/ja active Active
- 2021-03-31 CN CN202180039119.8A patent/CN115942976A/zh active Pending
- 2021-03-31 TW TW110112016A patent/TW202204388A/zh unknown
- 2021-03-31 BR BR112022019689A patent/BR112022019689A2/pt unknown
- 2021-03-31 KR KR1020227037408A patent/KR20220161404A/ko active Pending
- 2021-03-31 PH PH1/2022/552627A patent/PH12022552627A1/en unknown
- 2021-03-31 EP EP21780178.6A patent/EP4126247A4/en active Pending
- 2021-03-31 MX MX2022012311A patent/MX2022012311A/es unknown
- 2021-03-31 AU AU2021245922A patent/AU2021245922A1/en active Pending
- 2021-03-31 CA CA3172649A patent/CA3172649A1/en active Pending
- 2021-03-31 WO PCT/US2021/025103 patent/WO2021202675A1/en not_active Ceased
- 2021-03-31 IL IL296915A patent/IL296915A/en unknown
- 2021-03-31 US US17/995,163 patent/US20230151072A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022012311A (es) | 2023-01-05 |
| AU2021245922A1 (en) | 2022-10-13 |
| JP7735306B2 (ja) | 2025-09-08 |
| EP4126247A1 (en) | 2023-02-08 |
| PH12022552627A1 (en) | 2023-01-04 |
| US20230151072A1 (en) | 2023-05-18 |
| BR112022019689A2 (pt) | 2022-12-20 |
| EP4126247A4 (en) | 2024-04-24 |
| CN115942976A (zh) | 2023-04-07 |
| WO2021202675A1 (en) | 2021-10-07 |
| KR20220161404A (ko) | 2022-12-06 |
| TW202204388A (zh) | 2022-02-01 |
| JP2023520517A (ja) | 2023-05-17 |
| IL296915A (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7771076B2 (ja) | マスクされたｉｌ－１２サイトカイン及びその切断産物 | |
| JP7735306B2 (ja) | マスクされたｉｌ－２サイトカイン及びその切断産物 | |
| US20230331799A1 (en) | Masked il-15 cytokines and their cleavage products | |
| US12280120B2 (en) | Tumor-specific cleavable linkers | |
| US20230235006A1 (en) | Masked Cytokine Polypeptides | |
| US20260115302A1 (en) | Tumor-specific cleavable linkers | |
| HK40092028A (zh) | 掩蔽的il-2细胞因子和其切割产物 | |
| HK40090912A (zh) | 掩蔽的il-15细胞因子和其切割产物 | |
| EA049880B1 (ru) | Маскированные цитокиновые полипептиды |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250307 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250307 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250307 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250317 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250317 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250317 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250318 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250407 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250407 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250407 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250515 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20251114 Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20251114 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251114 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260203 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260203 |